{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-002125","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.009553+00:00","generated_at":"2026-05-27T07:57:07.326358+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Galectin Therapeutics elects all 11 director nominees, ratifies auditor at 2024 annual meeting","bullets":["All 11 director nominees elected with votes for ranging from 18.2M to 19.0M; broker non-votes of 20.0M.","Ratification of Cherry Bekaert LLP as auditor: 38.7M for, 162.8K against, 408.9K abstain.","Annual meeting held January 23, 2025; directors elected for term until next annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-002125","json":"https://secwatch.observer/filing/0001140361-25-002125.json","markdown":"https://secwatch.observer/filing/0001140361-25-002125.md","text":"https://secwatch.observer/filing/0001140361-25-002125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125002125/0001140361-25-002125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125002125/ef20042347_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:57:07.326358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}